Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michelle Phung
Drug Survival of Secukinumab in Real-World Plaque Psoriasis Patients: A 52-Week, Multicenter, Retrospective Study
Journal of the American Academy of Dermatology
Dermatology
Related publications
Real-World Drug Survival of Ixekizumab for Psoriasis
Journal of the American Academy of Dermatology
Dermatology
Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque Psoriasis: A Case Report
SAGE Open Medical Case Reports
Real‐World Evidence of Secukinumab in Psoriasis Treatment – A Meta‐Analysis of 43 Studies
Journal of the European Academy of Dermatology and Venereology
Dermatology
Infectious Diseases
Secukinumab: First IL-17A Antagonist for Plaque Psoriasis
Pharmacy Today
Characteristics of Chronic Plaque Psoriasis in Canada: A Retrospective Database Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy29 - Real-World Discontinuation of Biological Treatments in Moderate-To-Severe Plaque Psoriasis Over the First 5 Years of Treatment – A Literature Review of Drug Survival
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Secukinumab in Patients With Plaque Psoriasis: Area Under the Curve of Treatment Response Rates
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
